Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis®

2 Jun 2015

Maintenance therapy with lenalidomide benefits patients with multiple myeloma

A large cooperative-group study directed by the Alliance for Clinical Trials in Oncology has confirmed previous evidence that the drug lenalidomide delays time to disease progression for patients with multiple myeloma and is an important treatment option for patients with this rare but increasingly common cancer of the blood and marrow.

2 Jun 2015

Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

AbbVie, a global biopharmaceutical company, today announced findings from a Phase 2 study of the investigational medicine veliparib combined with the chemotherapy regimen carboplatin and paclitaxel that showed an improvement in median progression-free survival (PFS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC) who are current smokers.

2 Jun 2015

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Novartis is highlighting data from an ongoing Phase II clinical study of CTL019, an investigational chimeric antigen receptor (CAR) T cell therapy, that indicate its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma.

2 Jun 2015

Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen, in both solid and hematologic cancers.

2 Jun 2015

Mount Sinai Health System researchers present updates on cancer vaccine clinical trials at ASCO 2015

Mount Sinai Health System faculty will be presenting research updates on a lymphoma vaccine clinical trial, the best dosing for a drug against metastatic cancer, and new treatment strategies in relapsed multiple myeloma at the American Society of Clinical Oncology annual meeting, May 29 - June 2, 2015, in Chicago.

2 Jun 2015

BioLight Life Sciences reports operational and financial results for Q1 2015

BioLight Life Sciences Investments, a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today reported operational and financial results for the first quarter ended March 31, 2015.

1 Jun 2015

Abbvie presents venetoclax Phase 1 results in patients with multiple myeloma at ASCO 2015

AbbVie, a global biopharmaceutical company, today announced that results from a Phase 1b trial of investigational venetoclax, a novel inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, in combination with bortezomib and dexamethasone, showed an 83 percent overall response rate (n=5/6) in bortezomib-naive patients with relapsed/refractory (R/R) multiple myeloma, including two patients who achieved complete responses.1 These data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, May 31, in Chicago.

1 Jun 2015

$Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma$

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).

1 Jun 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14.

1 Jun 2015

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Data from the international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment with single-agent daratumumab – an investigational, human anti-CD38 monoclonal antibody – achieved an overall response rate (ORR) of 29.2 percent (95% CI, 20.8-38.9), as assessed by an independent review committee, in heavily pre-treated patients with multiple myeloma.

30 May 2015

Penn researchers to present clinical data at 2015 ASCO Annual Meeting

Researchers from the Abramson Cancer Center of the University of Pennsylvania and Penn's Perelman School of Medicine will present results from several clinical trials and other key studies during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 through June 2.

30 May 2015

Array BioPharma presents clinical data of BRAF, MEK and HER2 drugs at 2015 ASCO Annual Meeting

Array BioPharma Inc. today announced presentations on encorafenib, binimetinib and selumetinib (licensed to AstraZeneca) at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29 – June 2, 2015 in Chicago, Illinois.

29 May 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015.

28 May 2015

TGen and Baylor partnership set to increase treatment options for cancer patients

The Translational Genomics Research Institute (TGen) and Baylor Research Institute (BRI) at Dallas today announce an agreement that will focus on accelerating early detection and treatments for patients with a broad range of cancers.

22 May 2015

Nanoparticle-based therapy effective in treating mice with multiple myeloma

Researchers have designed a nanoparticle-based therapy that is effective in treating mice with multiple myeloma, a cancer of immune cells in the bone marrow.

21 May 2015

Johns Hopkins scientists safely use immune cells to treat multiple myeloma

In a report on what is believed to be the first small clinical trial of its kind, researchers at the Johns Hopkins Kimmel Cancer Center say they have safely used immune cells grown from patients' own bone marrow to treat multiple myeloma, a cancer of white blood cells.

21 May 2015

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, announces that it has signed an agreement with Genmab A/S to jointly research, develop and commercialize multiple bispecific antibodies for cancer immunotherapy using proprietary technologies from both companies: BioNTech's proprietary immunomodulatory antibodies and Genmab's DuoBody technology platform.

19 May 2015

Results from four major studies on cancer treatments to be presented at ASCO Annual Meeting

The American Society of Clinical Oncology today announced results from four major studies to be presented at ASCO's 51st Annual Meeting, May 29-June 2, in Chicago. Findings showed that use of a widely available vitamin pill reduces the risk of non-melanoma skin cancers; that early chemotherapy extends the lives of men with advanced prostate cancers; and that new therapies can improve outcomes for children with a rare form of kidney cancer and adults with relapsed multiple myeloma.

15 May 2015

AbbVie's venetoclax granted FDA Breakthrough Therapy Designation for CLL patients with 17p deletion

AbbVie today announced its investigational medicine venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, has been granted Breakthrough Therapy Designation by the FDA for the treatment of chronic lymphocytic leukemia (CLL) in previously treated (relapsed/refractory) patients with the 17p deletion genetic mutation.

6 May 2015

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

Maintenance therapy with lenalidomide benefits patients with multiple myeloma

Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015

Mount Sinai Health System researchers present updates on cancer vaccine clinical trials at ASCO 2015

BioLight Life Sciences reports operational and financial results for Q1 2015

Abbvie presents venetoclax Phase 1 results in patients with multiple myeloma at ASCO 2015

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Penn researchers to present clinical data at 2015 ASCO Annual Meeting

Array BioPharma presents clinical data of BRAF, MEK and HER2 drugs at 2015 ASCO Annual Meeting

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

TGen and Baylor partnership set to increase treatment options for cancer patients

Nanoparticle-based therapy effective in treating mice with multiple myeloma

Johns Hopkins scientists safely use immune cells to treat multiple myeloma

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

Results from four major studies on cancer treatments to be presented at ASCO Annual Meeting

AbbVie's venetoclax granted FDA Breakthrough Therapy Designation for CLL patients with 17p deletion

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in